Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
About this study
Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional salvage radiation. Salvage radiation after recurrence is successful in less than half of these men and most of those die from their disease. Measures to prevent recurrence are an important research priority for prostate cancer patients and their families. Hormonal therapy (androgen deprivation therapy; ADT) is routinely used to treat patients with metastases, but few clinical trials have examined if adjuvant ADT after surgery will prevent cancer recurrence. We aim to address this research oversight and test the hypothesis that for men at high risk of cancer recurrence, 1 year of ADT immediately after surgery will be safe and will significantly improve cancer outcomes.
- Condition
- Prostate Cancer
- Tested
- Lupron Depot
- Sponsor
- Ottawa Hospital Research Institute
Who can join
- Age
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 18 years
- Eligible sex: Male
- Study condition: Prostate Cancer
- undetectable PSA (\<0.02 ng/ml) within 16 weeks post-operative;
- ≥25% predicted risk of PSA recurrence within 5 years of surgery (based on the Kattan nomogram)
Exclusion 4
- Unwilling to receive ADT;
- previously received ADT;
- lymph node metastases
- allergy to any form of ADT
Where
3 sites, 3 recruiting
Nova Scotia Health
Halifax, Nova Scotia, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Centre universitaire de santé McGill - McGill University Health Centre
Montreal, Quebec, Canada
Contact
-
Rodney Breau, Dr.
613-737-8899 rbreau@toh.on.ca
Potential match only. Final eligibility is determined by the study team.